AI Article Synopsis
- Pantoprazole is a proton-pump inhibitor used for gastroesophageal disorders and as a preventive measure against stress ulcers and gastrointestinal bleeding in hospitalized patients.
- Hypersensitivity reactions to pantoprazole have been reported, but the extent of these reactions is not well understood, highlighting the need for more research in this area.
- A case study is presented of a 35-year-old male with no significant allergy history who developed an itchy skin rash a week after starting pantoprazole, with no other symptoms reported.
Article Abstract
Pantoprazole is a proton-pump inhibitor mainly used in treating various gastroesophageal disorders and frequently as prophylaxis for stress ulcers and gastrointestinal bleeding in most patients admitted for in-hospital management. Hypersensitivity reactions to this medication have been reported, although the exact incidence and prevalence are unknown. Further studies on proton-pump inhibitor allergic reactions should be conducted to enable physicians to safely select and prescribe an alternative type of medication within the same drug class, confidently avoiding the allergenic molecular compound that the patient reacted to previously. We present a case of a 35-year-old male postoperative bariatric patient with no significant allergy history who developed an allergic skin rash a week after being discharged on pantoprazole 40 mg. His rash was itchy and distributed mainly over the torso and lower limbs, without any additional respiratory or gastrointestinal symptoms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548015 | PMC |
| http://dx.doi.org/10.7759/cureus.44623 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrences and rechallenges of suspected drugs in epidermal necrolysis patients.
Clin Exp Dermatol
January 2025
Service de Dermatologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Créteil, France.
Background: Epidermal necrolysis (EN) is a rare and severe condition, characterized by a diffuse skin and mucosal detachment and mainly induced by drugs. Literature is scarce regarding the rate of recurrences and culprit drug re-exposure.
Objectives: To assess the rate of EN recurrences as well as high notoriety drugs re-exposures in patients with EN.
[Clinical update in critical care of pulmonary medicine 2024].
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
College of Pulmonary & Critical Care Medicine, Chinese PLA General Hospital, Beijing100091, China.
This review outlines significant clinical research developments in the field of critical care respiratory medicine from October 2023 to September 2024. In the post-pandemic era, the new global definition of acute respiratory distress syndrome (ARDS) has improved practicality and early warning capabilities, although further refinement through respiratory mechanics and multi-omics approaches is required. Novel patterns of pulmonary microbiota distribution in ARDS patients have emerged, with microbiota-host immune interactions significantly influencing clinical outcomes.
View Article and Find Full Text PDF[Translational Research on Pre-eclampsia with Existing Drugs Targeting Antioxidant Molecules].
Yakugaku Zasshi
January 2025
Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
Pre-eclampsia, a type of hypertensive disorders of pregnancy (HDP), is characterized by hypertension and organ dysfunction that develops or worsens after 20 weeks of gestation. Although symptomatic management using antihypertensive medications has been adopted, definitive treatments other than pregnancy termination remain unavailable to halt disease progression. Research on heme oxygenase (HO)-1, a molecule with anti-inflammatory and antioxidative properties, has shown that a pharmacological increase in placental HO-1 expression and activity may ameliorate this condition; therefore, HO-1 is a promising therapeutic target for this disorder.
View Article and Find Full Text PDFSuccessful resolution of refractory marginal ulcer with celiac artery stenting.
Clin J Gastroenterol
January 2025
University of Connecticut, Connecticut, USA.
Marginal ulcers are a common complication following Roux-en-Y bypass surgeries with an approximate incidence of 4.6%. The pathophysiology is complex and risk factors include smoking, nonsteroidal anti-inflammatory drugs (NSAIDs) use, Helicobacter pylori infection, and a larger pouch size.
View Article and Find Full Text PDFDrug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
ESMO Open
January 2025
Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA.
Background: Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy of anticancer agents. In the phase III PALLAS trial, the addition of palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use of PPIs affected survival outcomes in patients treated with palbociclib in PALLAS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!